The Sunset Test

When Should Healthcare Stop Investing?

Healthcare organizations know how to approve investments.

A new service line.

Another location.

A technology platform.

A recruitment initiative.

A transformation program.

The business case is presented.

The forecasts are reviewed.

The funding is approved.

But how often do leaders define the conditions under which that investment should end?

Organizations are generally much better at approving investments than ending them.

Once an initiative has funding, an executive sponsor, committed employees and a history of promises, stopping becomes an entirely different leadership challenge.

The question is no longer whether the investment deserves to begin.

It is whether it still deserves to continue.

The Commitment That Outlives Its Value

Healthcare leaders rarely continue funding initiatives for just one reason.

Sometimes results are disappointing, but leadership believes performance will improve.

Sometimes the original business case remains plausible, but market conditions have changed.

Sometimes an initiative delivers value, yet a competing opportunity now offers significantly greater strategic potential.

And sometimes, the most powerful reason for continuing is simply that the organization has already invested so much.

This is the sunk-cost trap: allowing past expenditure to influence a decision that should be based on future value.

The money already spent cannot be recovered by continuing. Yet stopping can feel like admitting failure, disappointing a sponsor or wasting earlier effort.

The uncomfortable possibility is that continuing an investment can feel responsible—even when it is no longer the best use of resources.

Introducing the Sunset Test™

I call this decision discipline the Sunset Test™:

A predefined set of strategic, financial, operational and risk-based conditions that determines when an initiative should lose funding, be fundamentally redesigned or be deliberately discontinued.

The Sunset Test is not a mandate to terminate every initiative that misses a target.

Healthcare investments can take time to mature. Clinical outcomes may require longer observation periods. New service lines may need time to establish referral patterns.

Innovation may generate valuable learning before it generates revenue.

The issue is not whether an initiative has encountered difficulty.

It is whether the evidence still justifies the resources committed to it.

That requires leaders to distinguish between three very different decisions:

• Continue: The strategic case remains sound and progress supports further investment.

• Redesign: The opportunity remains attractive, but the current model is not working.

• Sunset: The expected future value no longer justifies continued investment, or the risks and alternatives make withdrawal the stronger decision.

An initiative can remain strategically valid without deserving its current budget.

That distinction matters. The decision may not be to abandon a market, service or technology entirely. It may be to reduce its funding, narrow its scope, change its delivery model or transfer resources to a better-positioned initiative.

The Questions Leaders Avoid

The most useful sunset criteria are established before organizational attachment becomes entrenched.

When approving an investment, leaders should ask:

What evidence would cause us to stop or reduce funding?

If we were evaluating this initiative today, would we approve it again?

Are we continuing because future value remains compelling—or because stopping would be uncomfortable?

What higher-value opportunity is losing resources because this commitment remains in place?

Have market conditions changed enough to invalidate our original assumptions?

And the question that may provoke the greatest resistance:

If this initiative had never existed, would we commit these resources to it today?

These questions force leadership to assess the future rather than defend the past.

Why the Sunset Test Is a Competitive Advantage

Every continuing commitment consumes something scarce: capital, specialist talent, leadership attention, technology capacity or the organization's ability to pursue another opportunity.

The true cost of continuing is therefore not merely the initiative's budget.

It is also the value of what the organization cannot do instead.

This is particularly important for established healthcare groups. Mature service lines, long-standing contracts and internally sponsored projects can become difficult to challenge—even when the strategic landscape has shifted.

Research on sunk costs and strategic resource allocation, including work discussed by Harvard Business Review and McKinsey & Company, highlights the importance of evaluating decisions based on future consequences rather than allowing historical commitments to dictate the next move.

The goal is not to create a culture that abandons initiatives prematurely.

It is to create a leadership system in which continuation must remain justified, rather than becoming the default.

Make Stopping a Strategic Decision

At Phoenix MedStrategy, we help healthcare leaders establish the decision criteria, review mechanisms and resource-release disciplines that allow organizations to stop, redesign or reduce investments deliberately—not only after a crisis makes the decision unavoidable.

Because strategic maturity is not measured solely by the quality of investments an organization approves.

It is also measured by its willingness to release resources when the evidence changes.

The executive question is simple:

What would make us stop funding this?

If leadership cannot answer that question before the investment begins, it may be approving a commitment without defining its conditions for continuation.

The strongest allocation systems do not just decide what deserves funding. They decide what must happen for that funding to end.

Sources

Daniel Kahneman and Dan Lovallo, “Timid Choices and Bold Forecasts,” Harvard Business Review, 1993.

Richard Rumelt, Good Strategy/Bad Strategy: The Difference and Why It Matters, Crown Business, 2011.

McKinsey & Company, “The Power of Strategic Resource Allocation.”

Barry M. Staw, “The Escalation of Commitment to a Course of Action,” Academy of Management Review, 1981.